(Q61980705)
Statements
A Randomized, Double-blind, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination With Pegasys® and Ribavirin® (SOC) Versus SOC in Treatment-Naïve Patients With HCV Genotype 1 or 4 Infection (English)
0 references
February 2001
0 references
February 2012
0 references
413
0 references
18 year
0 references
65 year
0 references